FDA approves Bracco’s contrast agent for pediatric CNS imaging

The FDA has approved a label change to Bracco Diagnostics‘ MultiHance MRI contrast agent. The company’s product can now be used to visualize lesions with abnormal vascularity of the brain and spine in patients younger than two years old.

Data collected in pediatric patients under the age of two showed that a dose of 0.05 mmol/kg is effective at boosting the visualization of lesions in the brain and spine. Older kids and adults, however, need a dose of 0.1 mmol/kg.

Get the full story at our sister site, Drug Delivery Business News.

The post FDA approves Bracco’s contrast agent for pediatric CNS imaging appeared first on MassDevice.

from MassDevice http://ift.tt/2DZTQfi